Clinical Trial Update: Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial exploring neoadjuvant/adjuvant tislelizumab with anlotinib and platinum chemotherapy for resectable non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Non-Small Cell Lung Cancer, Anti Angiogenesis | Phase 2 | Status: NOT_YET_RECRUITING